How it works
Non-selectively activates melanocortin receptors. MC1R activation drives melanogenesis; MC4R activation produces the appetite-suppressant and erectogenic effects.
Structure: Cyclic heptapeptide α-MSH analogue
Reported benefits
- Increased melanin production and tanning
- Appetite suppression
- Increased libido and erectile function
Practical considerations
- Case reports link it to changing moles and melanoma diagnoses
- Non-selective receptor action means side effects are the rule, not the exception
- Bremelanotide (PT-141) is the regulated alternative for sexual-health goals only
Side effects and risks
- Nausea and facial flushing
- Darkening of existing moles and freckles
- Spontaneous erections
- Melanoma risk concerns
Melanotan II dosing overview
Loading 250–500 mcg daily, then weekly maintenance
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Reported loading | 250–500 mcg | Daily until desired pigmentation | Subcutaneous |
| Reported maintenance | 500 mcg–1 mg | Weekly | Subcutaneous |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Melanotan II FAQ
Why is Melanotan II considered risky?
It is a non-selective melanocortin agonist. Reported harms include nausea, spontaneous erections, new or darkening moles, and case reports of melanoma diagnosed after use — with no approval or quality control anywhere.
Does it protect against sunburn?
Increased eumelanin may reduce burning, but it is not sun protection and does not remove the need for sunscreen. UV exposure is still required for the tanning effect in most protocols.
How is it different from afamelanotide?
Afamelanotide (Scenesse) is an approved, selective MC1R agonist implant used for erythropoietic protoporphyria. Melanotan II is unapproved and hits multiple melanocortin receptors, which is why the side-effect profile is broader.
Research references
- Cardones & Grichnik, 2009 — α-MSH analogues and melanoma risk